

Ref No. NLL/CS/2019- 71

Date: 18.07.2019

1. National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Publication of Notice under Section 124(6) of the Company Act, 2013.

Sir's,

We are furnishing herewith newspaper Publication in respect of transfer of Equity Shares of the Company against which dividend remain unpaid/unclaimed for 7 conservative years, to Investor Education and Protection Fund (IEPF) pursuant to Rule 6 of the IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, which have been published in the following newspapers:

1. Business Standard (English-all editions) dated 18.07.2019.
2. Desh Sewak (Punjabi) dated 18.07.2019.

This is for your information and record please.

Yours Sincerely,

For Nectar Lifesciences Ltd.


SANJIV GOYAL
Chairman & Managing Director

Encl: a.a.

ure
neering
chedule 'A'
anizing a
y in River
19 at its
d on 10th
IPC in the
houdhary,

aking dur-
mpotence
re projects
so empha-
g theories
based on
ng ground

ploration &
of oil & gas
& III by win-
ed by lead-
DIL in a cer-
Pradhan,

ter of Steel,
locks under
ned that, the
the leading
& III basins
ploration in
roduction.
m & Assam
li Onshore, 1
erala-Konkan

EL

NECTAR LIFESCIENCES LIMITED
 Regd. Office: Vill. Saidpura, Tehsil Derabassi,
 Distt. S.A.S. Nager (Mohali), Punjab.
 CIN: L24232PB1995PLC018664 Tel No.: +91-1762-308000, 308001,
 Fax No.: +91-1762-308135 Email: cs@nectarlife.com, Website: www.nectarlife.com

TRANSFER OF SHARES AGAINST UNPAID/UNCLAIMED DIVIDEND TO THE INVESTOR EDUCATION AND PROTECTION FUND

In terms of requirement of Sections 124(6) and 125 of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (IEPF) (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended up to date (IEPF Rules), the shares in respect of which dividend has not been claimed or paid for seven consecutive years, are liable to be transferred to IEPF Authority.

As per the record of the Company, some of the Shareholder(s) have not claimed the dividend for the financial year 2011-12 and of the subsequent financial years. The detail of all such Shareholders and the shares due for transfer is displayed on the website of the Company i.e. on www.nectarlife.com under investor relation. The Company is also sending intimation at the latest available addresses individually to each of the shareholder(s), whose share(s) are liable to be transferred to IEPF under the said rules to claim the dividend. Please note that the unpaid or unclaimed amount of final dividend for the financial year (FY) 2011-12 will also be transferred to IEPF Authority in November, 2019.

Such Shareholder(s) are hereby called upon to contact Karvy Fintech Private Limited (Karvy), Shares Transfer Agent at the address mentioned below and send the undertaking (available on the website of the Company as detailed above) duly filled in and signed along with a self-attested copy of your PAN Card, Copy of Address Proof, a cancelled cheque accordingly, so that it will reach the Karvy before November 05, 2019 for claiming the unpaid dividends for financial year 2011-12 and onwards, failing which the Company shall proceed to transfer the underlying equity shares registered in your name to the credit of the IEPF Authority. Please note, however that on transfer of Shares to IEPF, you can claim from the IEPF Authority both your unclaimed dividend amount(s) and shares by making an application in Form - 5. The IEPF Rules and Form IEPF - 5 are available on the website at www.iepf.gov.in

Share Transfer Agent
 Karvy Fintech Private Limited (Unit: Nectar Lifesciences Limited)
 Karvy Selenium Tower B, Plot 31 - 32, Gachibowli,
 Financial District, Nankramguda, Hyderabad 500 032,
 Tel No.: +9140-67182222, Fax No. +9140-2300 1153,
 Email: pinward.ris@karvy.com, website: www.karvyfintech.com

For Nectar Lifesciences Limited
 Sd/-
 (Dinesh Dua)
 Chief Executive Officer & Director

Date: July 17, 2019
 Place: Chandigarh

UMANG DAIRIES LIMITED
 Regd. Office: Gajraula-Hasanpur Road, Gajraula - 244 235, Dist. Amroha (U.P.)
 Phone : 09557973504-5; CIN : L15111UP1992PLC014942
 Email : sharesumang@jkmall.com, Website : www.umangdairies.com

NOTICE

NOTICE is hereby given pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a meeting of the Board of Directors of the Company will be held on Wednesday, the 24th July 2019 at New Delhi, to consider and approve Unaudited Financial Results of the Company for the first quarter ended 30th June 2019.

This information is also available on the website of the Company viz. www.umangdairies.com and the websites of the Stock Exchanges where the Company's shares are listed viz. BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com).

For UMANG DAIRIES LIMITED
 Sd/-
 (Pankaj Kamra)
 Company Secretary

Place: New Delhi
 Date: 17.07.2019

apcotex industries limited
 Registered. Office: 49-53 Mahavir Centre, Sector 17,
 Vashi, Navi Mumbai - 400 703 Tel.: 022-2777 0800
www.apcotex.com Email: redressal@apcotex.com
 CIN: L99999MH1986PLC039199

NOTICE

Pursuant to Regulation 29 read with regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that a meeting of the Board of Directors of the company is scheduled to be held on Thursday, the 25th July 2019 inter-alia to consider and approve the audited financial results of the company for the quarter ended 30th June 2019.

The information contained in this notice is also available on the company's website www.apcotex.com and on the website of the Stock exchanges, www.bseindia.com and www.nseindia.com.

By order of the Board
 For apcotex industries limited
 Sd/-
 Anand V. Kumashi
 Company Secretary

Place: Navi Mumbai
 Date: 15th July, 2019

DCB BANK LIMITED
 CIN No.: L99999MH1995PLC089008
 Regd. Office: 601 & 602, 6th Floor, Tower A, Peninsula Business Park
 Senapati Bapat Marg, Lower Parel, Mumbai - 400013

DCB BANK

EXTRACT FROM UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 (₹ In crore)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2019 (Unaudited)	31.03.2019 (Audited)	30.06.2018 (Unaudited)	31.03.2019 (Audited)
1	Operating Profit before Provisions and Contingencies (Total income from operations (net of expenses))	166.54	185.28	141.41	646.60
2	Net Profit / (Loss) for the period from ordinary activities after tax	81.06	96.33	69.50	325.37
3	Net Profit / (Loss) for the period after tax (after Extraordinary items)	81.06	96.33	69.50	325.37
4	Equity Share Capital (Face value ₹ 10/-)	309.80	309.55	308.72	309.55
5	Reserves (excluding Revaluation Reserve)				2,560.52
6	Earnings Per Share (EPS)				
	(a) Basic and diluted EPS before Extraordinary items (net of tax expenses) for the period and for the previous periods	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Annualised)
	(i) Basic (₹)	2.62	3.11	2.26	10.53
	(ii) Diluted (₹)	2.57	3.06	2.21	10.36
	(b) Basic and diluted EPS after Extraordinary items (net of tax expenses) for the period and for the previous periods	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Annualised)
	(i) Basic (₹)	2.62	3.11	2.26	10.53
	(ii) Diluted (₹)	2.57	3.06	2.21	10.36

Note: The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The full format of the Financial Results is available on the Stock Exchange URLs as below:
 1. Bombay Stock Exchange: <https://www.bseindia.com/xml-data/corpfiling/AttachLive/a7a9c9ff-c446-4436-ab28-194d2b1caca3.pdf>
 2. National Stock Exchange: https://www.nseindia.com/corporate/BSESECoveringLetterResultsBoardMeeting16072019_16072019175836.zip
 The same is also available on the Bank's Website (www.dcbbank.com).

Place: Mumbai
 Date: July 16, 2019

For and on behalf of the Board of Directors
 Murali M. Natrajan
 MD & CEO